INFU services are provided under a two-platform model. The first platform is Patient Services, providing last-mile solutions for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient Services segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device Solutions segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
Cyborg Score Rationale
InfuSystem reported Q1 2026 net revenues of $33.7 million representing a 3% reduction from the prior year, net income of $1.0 million, and adjusted EBITDA margin expansion of 1% to 19%. In May 2026, the company announced a $20 million stock repurchase program authorized through June 30, 2028. The company operates in a stable healthcare segment with recurring revenue potential, though recent revenue contraction requires strategic focus.
Top Insights
In Q1 2026, the company reaffirmed full-year 2026 guidance despite a 3% revenue decline year-over-year.
Board approved a $20 million stock repurchase program (May 2026) through June 30, 2028, signaling management confidence in share valuation.
The company operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada, enabling local field-based support.
The core service within the Patient Services segment is the Oncology Business.
Named Competitors
Option Care Health — National provider of infusion and specialty pharmacy services
Aveanna Healthcare — Home and community-based healthcare services provider
Hospice & Palliative Care — Home health, hospice and personal care services
Infusion Pumps — Medical device manufacturer including infusion systems
Recent Developments
(May 2026) Announced $20 million stock repurchase program (July 1, 2026–June 30, 2028)